BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33627486)

  • 21. Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia.
    Li Y; Seet CS; Mack R; Joshi K; Runde AP; Hagen PA; Barton K; Breslin P; Kini A; Ji HL; Zhang J
    Stem Cell Reports; 2024 Jan; 19(1):100-111. PubMed ID: 38101400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Learning from mouse models of MLL fusion gene-driven acute leukemia.
    Schwaller J
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.
    Sakamoto K; Imamura T; Yano M; Yoshida H; Fujiki A; Hirashima Y; Hosoi H
    Blood Cancer J; 2014 Apr; 4(4):e205. PubMed ID: 24769646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).
    Pigneux A; Labopin M; Maertens J; Cordonnier C; Volin L; Socié G; Blaise D; Craddock C; Milpied N; Bacher U; Malard F; Esteve J; Nagler A; Mohty M;
    Leukemia; 2015 Dec; 29(12):2375-81. PubMed ID: 26082270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.
    Balgobind BV; Zwaan CM; Pieters R; Van den Heuvel-Eibrink MM
    Leukemia; 2011 Aug; 25(8):1239-48. PubMed ID: 21566656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.
    Buechele C; Breese EH; Schneidawind D; Lin CH; Jeong J; Duque-Afonso J; Wong SH; Smith KS; Negrin RS; Porteus M; Cleary ML
    Blood; 2015 Oct; 126(14):1683-94. PubMed ID: 26311362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements.
    Liu J; Qin YZ; Yang S; Wang Y; Chang YJ; Zhao T; Jiang Q; Huang XJ
    Ann Hematol; 2017 Apr; 96(4):567-574. PubMed ID: 28054140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
    Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
    Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells.
    Dong F; Bai H; Wang X; Zhang S; Wang Z; Xie M; Zhang S; Wang J; Hao S; Cheng T; Ema H
    Blood Adv; 2019 Feb; 3(3):419-431. PubMed ID: 30733302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid.
    Classen CF; Teigler-Schlegel A; Röttgers S; Reinhardt D; Döhner K; Debatin KM
    Ann Hematol; 2005 Nov; 84(12):774-80. PubMed ID: 16044313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny.
    Horton SJ; Jaques J; Woolthuis C; van Dijk J; Mesuraca M; Huls G; Morrone G; Vellenga E; Schuringa JJ
    Leukemia; 2013 Apr; 27(5):1116-26. PubMed ID: 23178754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
    Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
    Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
    Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.
    Zhang Y; Yan X; Sashida G; Zhao X; Rao Y; Goyama S; Whitman SP; Zorko N; Bernot K; Conway RM; Witte D; Wang QF; Tenen DG; Xiao Z; Marcucci G; Mulloy JC; Grimes HL; Caligiuri MA; Huang G
    Blood; 2012 Aug; 120(5):1118-29. PubMed ID: 22740449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
    Faber J; Krivtsov AV; Stubbs MC; Wright R; Davis TN; van den Heuvel-Eibrink M; Zwaan CM; Kung AL; Armstrong SA
    Blood; 2009 Mar; 113(11):2375-85. PubMed ID: 19056693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.